NeuroBo Pharmaceuticals News

NeuroBo Pharmaceuticals | EFFECT: Others

Apr 24 06:08 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Apr 17 08:34 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Apr 16 16:36 ET

NeuroBo Pharmaceuticals | S-3: Registration statement for specified transactions by certain issuers

Apr 12 16:09 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Apr 1 08:31 ET

NeuroBo Pharmaceuticals | 10-K: Annual report

Mar 28 22:26 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update

Mar 28 08:05 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Mar 13 08:33 ET

NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Woodworth Marshall H

Mar 4 21:21 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer

Mar 4 07:35 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

Feb 29 08:33 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc. Posted an Updated Corporate Presentation

Feb 14 08:56 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

Feb 1 08:31 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating Da-1241 for the Treatment of Mash

Jan 18 00:00 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement

Jan 9 00:00 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals Submits Ind Application to the Fda for a Phase 1 Clinical Trial of Da-1726 for the Treatment of Obesity

Dec 28, 2023 00:00 ET

NeuroBo Pharmaceuticals | 8-K: NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Dec 19, 2023 09:03 ET

NeuroBo Pharmaceuticals | 8-K: Neurobo Pharmaceuticals, Inc Posted an Updated Corporate Presentation

Dec 7, 2023 09:20 ET

NeuroBo Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Tursi James Patrick

Dec 4, 2023 17:12 ET

NeuroBo Pharmaceuticals: Q3 2023 Earnings Report

Nov 13, 2023 16:29 ET